Business Development Deal Architecture
  • Search OnBioBD:

  • OnBioBD OldSkool NEWS:

    - OnBioVC 4Q11 Trend Analysis, now available
    - OnBioVC 1Q12 White Paper, now available
    - OnBioVC 1Q12 Trend Analysis, coming soon

  • FDA Registered Contract Manufacturer

Eviagenics (France) a development-stage biotechnology company focused on in vivo recombination manufacturing technologies, closed a $1.7M Series A financing. Participants include Emertec Management, CEA Investissement and CapDecisif Management.

NanoInk (Skokie, IL) a commercial-stage a protein analysis, biomaterial manufacturing and biodiscovery assay kit developer, closed a$65M Series E financing. Participants include Lurie Investment Fund.

Direvo (Germany) a commercial-stage enzyme engineering and strain development platform for industrial biotechnology applications, closed a $8.1M Series D financing. Participants include TVM Capital and NRW Bank.

PolyTherics (United Kingdom) a clinical-stage protein engineering company focused on site-specific PEGylation of biologics, closed a $4M Series C financing. Participants include Imperial Innovations, Longbow Capital and The Capital Fund.

PhaseBio Pharmaceuticals (Research Triangle Park, NC) a development-stage biopharma company focused on elastin-like fusion proteins for improved expression and purification of biological, closed a $25M Series B financing. Participants include New Enterprise Associates, Hatteras Venture Partners, Johnson & Johnson Development Corp. and Fletcher Spaght Ventures.

Pfenex (San Diego, CA) a commercial-stage biotechnology company focused on recombinant protein expression for a broad range of applications including therapeutic proteins, vaccines, research, reagents and biosimilars, closed a $24M Series A financing. Participants include Signet Healthcare Partners. Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

CEVEC Pharmaceuticals (Germany) a biopharmaceutical company focused on developing and producing therapeutic proteins and monoclonal antibodies with human glycosylation patterns, closed a $5.4M Series B financing. Participants include Creathor Venture, NRW Bank, Sparkasse KolnBonn and ERP Startfonds. Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

BioVex (Woburn, MA) a clinical-stage biologics company focused on metastatic melanoma, head and neck, pancreatic and colo-rectal cancer, closed a $30M Series F bringing the entire round to $70M. Participants have included Morningside Venture, Ventech, MVM Life Science Partners, Sectoral Asset Management, Ysios Capital Partners, Forbion Capital Partners, Credit Agricole Private Equity, Harris & Harris […]

Xcellerex (Marlborough, MA) a bioprocess and biologics manufacturer raised $11M in the second closing of a Series B financing, the total raised in the round was $20M. The round was led by the SCG Group and Kleiner Perkins Caufield & Byers.

  

to top of page...